BUPROPION TREATMENT FOR YOUTH SMOKING CESSATION

描述：（申请人的描述） 烟草使用仍然是导致过早死亡的主要可预防原因， 美国，如果我们在这方面取得进展， 尼古丁依赖的治疗不会发生。 虽然批准 迄今为止，用于戒烟的药物是那些提供尼古丁的药物。 替代，最近的研究评估的影响，新的非尼古丁 药物治疗表明，戒烟率的显着改善可能是 可能 最有前途的非尼古丁药物之一是安非他酮（Zyban）。 安非他酮已被用作抗抑郁药， 可用性，从而提高情绪，并将被FDA批准为吸烟 停止用药。 此外，它已被调查作为一种药物 用于治疗青少年注意力缺陷/多动障碍。 因为安非他酮对于成人戒烟的疗效更大 因为安非他酮的安全性已经被 在青年中显示，它是作为药理学研究的明确选择。 青少年戒烟治疗。 因为吸烟的最佳剂量 尚未在青年中评估戒烟，一项剂量范围研究， 安非他酮用于青少年戒烟的安全性和有效性 提出了 本研究是一项随机、双盲、 安慰剂对照临床试验，旨在评估（1）安非他酮 剂量，如果有的话，增加禁欲率超过安慰剂，和（2） 因素，如药物依从性，尼古丁依赖和动机 影响治疗效果 拟议的研究有许多潜在的好处。 的 拟议研究的结果可能有助于更好地了解如何 使用药物治疗青少年戒烟。 开始 烟草使用在很大程度上是一个社会文化过程，尼古丁依赖是一个 医疗条件，其治疗是优化时，充分的医疗设施， 提供医疗护理。 拟议的研究将遵循机构的 戒烟的医疗保健政策和研究指南，包括 一种结合行为学和药理学的医学模式方法， 在卫生保健环境中进行干预。 虽然许多研究 评估成人戒烟方法，仍然缺乏研究 评估促进青少年戒烟的方法。 这么少 在此基础上进行扩展的研究，拟议的研究可能会导致重要的 对青少年吸烟过程和机制的新认识 停止

DESCRIPTION: (Applicant's Description) Tobacco use remains the leading preventable cause of premature death in the U.S., and this public health problem will remain so if advances in the treatment of nicotine dependence do not occur. While the approved medications for smoking cessation to date are those that provide nicotine replacement, recent studies evaluating the effects of novel non-nicotine medications suggest that significant improvements in cessation rates may be possible. One of the most promising non-nicotine medications is bupropion (Zyban). Bupropion has been available as an antidepressant that increases dopamine availability and thus elevates mood, and will be FDA approved as a smoking cessation medication. Furthermore, it has been investigated as a medication for the treatment of attention deficit/hyperactivity disorder in youth. Because the efficacy of bupropion for adult smoking cessation is greater than nicotine replacement, and because the safety of bupropion has been shown in youth, it is the clear choice for investigation as a pharmacologic treatment for youth smoking cessation. Since the optimal dose for smoking cessation has not been assessed in youth, a dose ranging study to evaluate the safety and efficacy of bupropion for smoking cessation in youth is proposed. The proposed study is a randomized, double-blind, placebo-controlled clinical trial designed to assess (1) which bupropion dose, if any, increases abstinence rates over placebo, and (2) which factors, such as medication adherence, nicotine dependence, and motivation to quit, affect treatment outcome. There are a number of potential benefits from the proposed study. The results of the proposed study could lead to a better understanding of how to use a pharmacologic treatment for youth smoking cessation. Initiation of tobacco use is largely a sociocultural process, nicotine dependence is a medical condition whose treatment is optimized when the full armamentarium of medical care is provided. The proposed study will follow Agency for Health Care Policy and Research guidelines for smoking cessation, including a medical model approach that combines behavioral and pharmacologic intervention within a health care environment. While many studies have evaluated cessation methods for adults, there remains a dearth of research evaluating methods for enhancing youth smoking cessation. With so little research upon which to expand, the proposed study could lead to important new understandings regarding the process and mechanisms of youth smoking cessation.